2017
DOI: 10.1136/vr.104135
|View full text |Cite
|
Sign up to set email alerts
|

RHDV2 overcoming RHDV immunity in wild rabbits (Oryctolagus cuniculus) in Australia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
32
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 38 publications
(47 citation statements)
references
References 26 publications
2
32
1
Order By: Relevance
“…Due to the limited information of the vaccination status of domestic rabbits in this study and, perhaps more importantly, the lack of information about numbers of vaccinated rabbits that have survived GI.2 infection, it is not possible to estimate the effectiveness of the GI.1 vaccine in preventing disease caused by GI.2. However, the detection of GI.2 in 15 vaccinated domestic rabbits supports previous work demonstrating that cross-protection between GI.1 and GI.2 is at best incomplete, and a vaccine covering GI.2 is urgently needed to protect farmed and pet rabbits in Australia (20).…”
supporting
confidence: 75%
See 1 more Smart Citation
“…Due to the limited information of the vaccination status of domestic rabbits in this study and, perhaps more importantly, the lack of information about numbers of vaccinated rabbits that have survived GI.2 infection, it is not possible to estimate the effectiveness of the GI.1 vaccine in preventing disease caused by GI.2. However, the detection of GI.2 in 15 vaccinated domestic rabbits supports previous work demonstrating that cross-protection between GI.1 and GI.2 is at best incomplete, and a vaccine covering GI.2 is urgently needed to protect farmed and pet rabbits in Australia (20).…”
supporting
confidence: 75%
“…Based on these data, the GI.2 infection rate was higher than would have been expected with GI.1 alone, and GI.1 detections were well below what would be expected normally. This replacement may have been driven by the lack of immunological cross-protection against GI.2 afforded by the Cylap RCD vaccine (Zoetis Australia) or previous GI.1 infection (20), leading to a large number of susceptible individuals at the start of the epidemic. In addition, the ability of GI.2 to cause lethal infection in young rabbits at a much higher rate than GI.1 (8) implies that new cohorts of rabbits are becoming susceptible to severe outbreaks of GI.2 at an earlier age, which likely provides a strong competitive advantage for virus transmission in the field.…”
mentioning
confidence: 99%
“…The reciprocal positive association between RHDV and the rate of increase of RHDV2 was most likely the result of partial cross‐immunity, where some RHDV seropositive individuals are susceptible to RHDV2 infection. RHDV2 can overcome immunity from previous RHDV infection or vaccination (Le Gall‐Reculé et al, ; Neave et al, ; Peacock et al, ) and partial cross‐immunity has been recognized as a key process facilitating the incursion and coexistence of competing pathogen strains (Adams & Sasaki, ; Best & Hoyle, ). Several outcomes from the competition among strains under partial cross‐immunity are possible, including strain extinction, coexistence or strain oscillation (Lion & Metz, ; Restif & Grenfell, ).…”
Section: Discussionmentioning
confidence: 99%
“…However, other studies using more recent RHDV2 isolates report very high levels of virulence in both adult and young rabbits (Capucci, Cavadini, Schiavitto, Lombardi, & Lavazza, ; Neimanis, Pettersson, Huang, Widén, & Strive, ). Unlike RHDV (Robinson, So, Müller, Cooke, & Capucci, ), RHDV2 causes fatal infections in juvenile rabbits <5 weeks of age (Neave et al, ) and can also infect rabbits recovered from previous RHDV infection or vaccination (Le Gall‐Reculé et al, ; Neave et al, ; Peacock et al, ). Initial estimates of the impact of RHDV2 on wild populations from two sites in South Australia indicated a reduction in rabbit abundance of around 80% (Mutze et al, ).…”
Section: Introductionmentioning
confidence: 99%
“…During the first RHDV2 outbreak emergency vaccination with classical myxomatosis/RHDV vaccine was reported to offer some protection, reducing mortality within seven to 15 days (Bárcena and others 2015); however, conflicting information has since emerged (Peacock and others 2017). Cross-protection between variants is variable and difficult to predict.…”
Section: Available Vaccines and Cross-protectionmentioning
confidence: 99%